These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36154887)

  • 41. [Severe 46,XY virilization deficit due to 17beta-hydroxysteroid dehydrogenase deficiency].
    Twesten W; Johannisson R; Holterhus PM; Hiort O
    Klin Padiatr; 2002; 214(5):314-5. PubMed ID: 12235550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 46,XY DSD due to 17β-HSD3 deficiency and 5α-reductase type 2 deficiency.
    Inacio M; Sircili MH; Brito VN; Domenice S; Oliveira-Junior AA; Arnhold IJ; Tibor FD; Costa EM; Mendonca BB
    Adv Exp Med Biol; 2011; 707():9-14. PubMed ID: 21691945
    [No Abstract]   [Full Text] [Related]  

  • 45. Demethoxylation of curcumin enhances its inhibition on human and rat 17β-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis.
    Ji Z; Sang J; Wang H; Xia M; Hao T; Chen L; Lu H; Wang S; Yao M; Li L; Ge RS
    Food Chem Toxicol; 2024 Apr; 186():114489. PubMed ID: 38360388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenotypic and molecular characteristics in eleven Chinese patients with 5α-reductase Type 2 deficiency.
    Zhu H; Liu W; Han B; Fan M; Zhao S; Wang H; Lu Y; Pan C; Chen F; Chen M; Song H; Cheng K; Qiao J
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):711-20. PubMed ID: 24665940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred.
    Can S; Zhu YS; Cai LQ; Ling Q; Katz MD; Akgun S; Shackleton CH; Imperato-McGinley J
    J Clin Endocrinol Metab; 1998 Feb; 83(2):560-9. PubMed ID: 9467575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 17 beta-hydroxysteroid dehydrogenase 3 deficiency in the Mediterranean population.
    Rosler A
    Pediatr Endocrinol Rev; 2006 Aug; 3 Suppl 3():455-61. PubMed ID: 17551466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
    Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification and functional analysis of fourteen NR5A1 variants in patients with the 46 XY disorders of sex development.
    Na X; Mao Y; Tang Y; Jiang W; Yu J; Cao L; Yang J
    Gene; 2020 Nov; 760():145004. PubMed ID: 32738419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of gene mutations in a Chinese 46,XY disorders of sex development cohort detected by targeted next-generation sequencing.
    Yu BQ; Liu ZX; Gao YJ; Wang X; Mao JF; Nie M; Wu XY
    Asian J Androl; 2021; 23(1):69-73. PubMed ID: 32985417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
    Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
    Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pubertal Development in
17Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency
.
    Hiort O; Marshall L; Birnbaum W; Wünsch L; Holterhus PM; Döhnert U; Werner R
    Horm Res Paediatr; 2017; 87(5):354-358. PubMed ID: 27951541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical, Hormonal, and Genetic Spectrum of 46 XY Disorders of Sexual Development (DSD) Patients.
    Palui R; Ravichandran L; Kamalanathan S; Chapla A; Sahoo J; Narayanan N; Naik D; Thomas N
    Indian J Pediatr; 2024 May; ():. PubMed ID: 38761274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3.
    Cheng Y; Yang Y; Wu Y; Wang W; Xiao L; Zhang Y; Tang J; Huang YD; Zhang S; Xiang Q
    Front Pharmacol; 2020; 11():637. PubMed ID: 32457626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
    Bertelloni S; Maggio MC; Federico G; Baroncelli G; Hiort O
    Gynecol Endocrinol; 2006 Sep; 22(9):488-94. PubMed ID: 17071532
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.